Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Teresa Mercade Macarulla

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5856-4082; OpenAlex author ID A5082191671. Sources: OpenAlex.

Their work

Papers
86 (first author 7, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
318
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers · 2017: 4 papers · 2018: 7 papers · 2019: 9 papers · 2020: 8 papers · 2021: 12 papers · 2022: 2 papers · 2023: 10 papers · 2024: 6 papers · 2025: 10 papers · 2026: 11 papers

Papers 50 of 86

  1. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. Co-author DOI 10.1016/j.ejca.2026.116683↗
  2. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  3. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  4. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  5. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. Co-author DOI 10.1038/s41591-026-04705-y↗
  6. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2600752↗
  7. Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals. Co-author DOI 10.1080/1120009x.2026.2639277↗
  8. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Co-author DOI 10.1093/oncolo/oyag023↗
  9. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With N… First author DOI 10.1097/coc.0000000000001253↗
  10. Utility of archived EUS-guided fine-needle biopsy samples for next-generation sequencing in pancreatic adenocarcinoma. Co-author DOI 10.1097/eus.0000000000000197↗
  11. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Ph… Co-author DOI 10.1158/1078-0432.ccr-26-0805↗
  12. Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors Last author DOI 10.1016/j.annonc.2025.06.018↗
  13. Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, It… Co-author DOI 10.1016/j.esmogo.2025.100217↗
  14. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… First author DOI 10.1016/j.esmoop.2025.105534↗
  15. Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. Co-author DOI 10.1016/j.esmorw.2025.100116↗
  16. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  17. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  18. Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarc… Co-author DOI 10.1177/17588359241309828↗
  19. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  20. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  21. Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line … Co-author DOI 10.64898/2025.12.14.25342225↗
  22. Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology. Co-author DOI 10.1007/s12094-024-03386-8↗
  23. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Last author DOI 10.1016/s1470-2045(24)00263-8↗
  24. Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. Co-author DOI 10.1056/evidoa2300144↗
  25. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  26. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  27. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Me… Co-author DOI 10.3390/cancers16071323↗
  28. Assessment of the level III of Inoue by preoperative endoscopic ultrasound and elastography: a novel approach to predict a periarterial divestment technique in… Co-author DOI 10.1007/s00423-023-03105-x↗
  29. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. First author DOI 10.1016/j.ctrv.2022.102502↗
  30. Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2023.102604↗
  31. Clinical and genomic characterisation of early-onset pancreatic cancer. Last author DOI 10.1016/j.ejca.2023.113338↗
  32. Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. Last author DOI 10.1016/j.esmogo.2023.08.010↗
  33. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  34. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study P… Co-author DOI 10.1093/oncolo/oyad022↗
  35. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world stud… Last author DOI 10.1186/s12885-023-11377-1↗
  36. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. Co-author DOI 10.1186/s13073-023-01171-w↗
  37. Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette St… Co-author DOI 10.3390/cancers15235603↗
  38. Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. Co-author DOI 10.1007/s12094-021-02674-x↗
  39. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  40. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. Co-author DOI 10.1002/psp4.12725↗
  41. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcino… Co-author DOI 10.1007/s00280-020-04214-w↗
  42. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Last author DOI 10.1016/j.annonc.2021.01.070↗
  43. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Co-author DOI 10.1016/j.ejca.2021.03.028↗
  44. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A … First author DOI 10.1016/j.pan.2020.10.029↗
  45. Emerging Treatment Strategies in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001845↗
  46. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Co-author DOI 10.1136/jitc-2020-002068↗
  47. The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. Co-author DOI 10.1158/0008-5472.can-20-4263↗
  48. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… First author DOI 10.1158/1078-0432.ccr-21-0929↗
  49. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  50. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with… Co-author DOI 10.1245/s10434-021-09816-z↗

Closest collaborators

The 25 strongest of 318 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Pazo-Cid · 15 shared papers, 2017–2026 · strength 2.56
  2. Eileen Mary O'Reilly · 15 shared papers, 2013–2026 · strength 2.15
  3. Eric Van Cutsem · 17 shared papers, 2018–2026 · strength 2.09
  4. Davide Melisi · 13 shared papers, 2018–2026 · strength 2.03
  5. Florian Castet · 8 shared papers, 2023–2026 · strength 1.73
  6. Zev A. Wainberg · 9 shared papers, 2021–2026 · strength 1.69
  7. Tanios Bekaii‐Saab · 9 shared papers, 2019–2026 · strength 1.48
  8. Manuel M. Hidalgo · 14 shared papers, 2013–2026 · strength 1.45
  9. Jaime Feliú · 11 shared papers, 2016–2025 · strength 1.45
  10. Gerald W. Prager · 7 shared papers, 2019–2026 · strength 1.28
  11. Alfredo Carrato · 11 shared papers, 2015–2025 · strength 1.27
  12. Do‐Youn Oh · 10 shared papers, 2019–2026 · strength 1.16
  13. Michele Reni · 11 shared papers, 2014–2023 · strength 1.05
  14. Richard A Hubner · 6 shared papers, 2017–2026 · strength 1.05
  15. Rocio García‐Carbonero · 8 shared papers, 2018–2026 · strength 1.04
  16. Pascal R. Hammel · 11 shared papers, 2014–2025 · strength 1.00
  17. Andrew Scott Paulson · 5 shared papers, 2023–2026 · strength 0.99
  18. Shubham Pant · 5 shared papers, 2023–2026 · strength 0.99
  19. Jens Thomas Siveke · 7 shared papers, 2018–2026 · strength 0.89
  20. Rafael Álvarez-Gallego · 6 shared papers, 2017–2026 · strength 0.81
  21. Jean‐Frédéric Blanc · 6 shared papers, 2019–2025 · strength 0.81
  22. Carmen Guillén‐Ponce · 7 shared papers, 2017–2026 · strength 0.80
  23. Ana P. Vivancos · 5 shared papers, 2017–2026 · strength 0.79
  24. Josep M. Tabernero · 9 shared papers, 2014–2023 · strength 0.78
  25. Mariano Ponz‐Sarvisé · 5 shared papers, 2020–2026 · strength 0.74

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.